Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis

Cancer

Volumn 115, Issue 20, 2009, Pages 4737-4744

  Konoplev, Sergej ^a   Xuelin, Huang ^a   Drabkin, Harry A ^b   Koeppen, Hartmut ^a   Jones, Dan ^a   Kantarjian, Hagop M ^a   Garcia Manero, Guillermo ^a   Weina, Chen ^a   Medeiros, L Jeffrey ^a   Bueso Ramos, Carlos E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

AML; FLT3 ITD; Immunohistochemical analysis; NPM1 mutation; Prognosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ARSENIC TRIOXIDE; AZACITIDINE; CD135 ANTIGEN; CD34 ANTIGEN; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOXANTRONE; MYELOTARG; NUCLEOPHOSMIN; RETINOIC ACID; SERUM ALBUMIN; SORAFENIB; TIOGUANINE; TOPOTECAN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLAST CELL; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; CYTOPLASM; DNA SEQUENCE; DRUG MEGADOSE; EVENT FREE SURVIVAL; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 70350091450     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24543     Document Type: Article

References (20)

1. Cordell JL, Pulford KA, Bigerna B, et al. Detection of normal and chimeric nucleophosmin in human cells. Blood. 1999;93:632-642. (Pubitemid 29035746)
2. Chang JH, Olson MO. Structure of the gene for rat nucleolar protein B23. J Biol Chem. 1990;265:18227-18233. (Pubitemid 20382178)
3. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106:3733-3739. (Pubitemid 41739006)
4. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood. 2005;106:3618-3620. (Pubitemid 41609201)
5. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740-3746. (Pubitemid 41739007)
6. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909-1918. (Pubitemid 351620111)
7. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109:431-448.
8. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254-266. (Pubitemid 40110814)
9. Falini B, Martelli MP, Bolli N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006;108:1999-2005. (Pubitemid 44395013)
10. Onciu M, Schlette E, Medeiros LJ, Abruzzo LV, Keating M, Lai R. Cytogenetic findings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities. Am J Clin Pathol. 2001;116:886-892. (Pubitemid 33108160)
11. Chen W, Jones D, Medeiros LJ, Luthra R, Lin P. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. Br J Haematol. 2005;130:726-728. (Pubitemid 43906644)
12. Estey EH, Pierce S, Keating MJ. Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica. 2000;85:246-249. (Pubitemid 30340139)
13. Chou WC, Tang JL, Lin LI, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res. 2006;66:3310-3316.
14. Cazzaniga G, Dell'Oro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood. 2005;106:1419-1422. (Pubitemid 41129610)
15. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011-4020. (Pubitemid 43726809)
16. Weinberg JM, A Beck, M Seetharam, J Gotlib, J Zehnder, DA Arber. Significance of NPM1 and FLT3 mutations in acute myeloid leukemia with multilineage dysplasia: does NPM1 identify a lower risk group? [abstract] Modern Pathology. 2008;21(suppl 1s):281.
17. Wandt H, Schakel U, Kroschinsky F, et al. MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood. 2008;111:1855-1861.
18. Bardet V, Costa LD, Elie C, et al. Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype. Leukemia. 2006;20:1644-1646. (Pubitemid 44264119)
19. Albiero E, Madeo D, Bolli N, et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia. 2007;21:1099-1103. (Pubitemid 46672090)
20. Falini B, Albiero E, Bolli N, et al. Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif. Leukemia. 2007;21:2052-2054; author reply 2054; discussion 2055-2056.